Study summary
A PD-L1 and VEGF bispecific antibody shrank tumors in about three in four patients
73.8%of tumors shrank
What was tested
Pumitamig, an antibody blocking both PD-L1 and VEGF, with nab-paclitaxel as first treatment for advanced TNBC. Single-arm trial in China, no comparison group.
What they found
- Tumors shrank in 73.8%.
- Low white blood cell counts and protein in the urine were the main severe side effects.
What it means
Now in the phase 3 ROSETTA Breast-01 trial run by BioNTech.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.